The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 05, 2022

Filed:

Dec. 08, 2015
Applicants:

Mark D. Ayers, Pennington, NJ (US);

Andrey Loboda, Canton, MA (US);

Jared K. Lunceford, Washington, UT (US);

Terrill K. Mcclanahan, Sunnyvale, CA (US);

Erin E. Murphy, Redwood City, CA (US);

Michael Nebozhyn, Colmar, PA (US);

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Mark D. Ayers, Pennington, NJ (US);

Andrey Loboda, Canton, MA (US);

Jared K. Lunceford, Washington, UT (US);

Terrill K. McClanahan, Sunnyvale, CA (US);

Erin E. Murphy, Redwood City, CA (US);

Michael Nebozhyn, Colmar, PA (US);

Assignee:

Merck Sharp & Dohme LLC, Rahway, NJ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); G16B 20/00 (2019.01); G16B 30/00 (2019.01); G16B 40/00 (2019.01); C07K 16/28 (2006.01); C12Q 1/68 (2018.01); G16B 40/30 (2019.01); G16B 20/20 (2019.01); G16H 50/30 (2018.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C07K 16/2818 (2013.01); C12Q 1/68 (2013.01); G16B 20/00 (2019.02); G16B 20/20 (2019.02); G16B 30/00 (2019.02); G16B 40/00 (2019.02); G16B 40/30 (2019.02); G16H 50/30 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01);
Abstract

A gene expression platform, which is a combination of a set of genes that are correlated with response to a PD-1 antagonist in multiple tumor types and a normalization gene set, is disclosed. A method and system of using the gene expression platform to derive gene signature biomarkers of anti-tumor response to a PD-1 antagonist and to test patient samples for predictive gene signature biomarkers are also disclosed.


Find Patent Forward Citations

Loading…